A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumab in Patients With Active Psoriatic Arthritis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Risankizumab (Primary)
- Indications Psoriatic arthritis
- Focus Proof of concept; Therapeutic Use
- Sponsors AbbVie; Boehringer Ingelheim
- 05 Apr 2017 Planned End Date changed from 1 Sep 2017 to 1 Aug 2017.
- 31 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Apr 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.